Previous 10 | Next 10 |
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis PR Newswire Clinical Success Achieved in Second Cohort of Patients PRINCETON, N.J. , Jan. 4, 2024 /PRNewswire/ -- So...
2024-01-02 10:09:39 ET DENVER, Colo., Jan. 2, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Longboard Pharmaceuticals Inc (NASDAQ: LBPH), Voyager Therapeutics Inc (NASDAQ: VYGR), Soligenix Inc (NASDAQ: ...
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses PR Newswire Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal virus...
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery PR Newswire HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J. , Dec. 1, 2023 /PRNewswire/ --...
2023-11-30 14:00:55 ET More on Soligenix Seeking Alpha’s Quant Rating on Soligenix Historical earnings data for Soligenix Financial information for Soligenix For further details see: Soligenix wins FDA nod to conduct trial for rare disease therapy
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease PR Newswire Pipeline Expansion of Novel Innate Defense Regulator Technology PRINCETON, N.J. , Nov. 30, 2023 /PRN...
2023-11-13 07:50:45 ET More on Soligenix Seeking Alpha’s Quant Rating on Soligenix Historical earnings data for Soligenix Financial information for Soligenix For further details see: Soligenix GAAP EPS of -$0.16 beats by $0.13, revenue of $0.1M mis...
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results PR Newswire PRINCETON, N.J. , Nov. 13, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on devel...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Soligenix Inc. (SNGX) is expected to report $-0.44 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's ( Nasdaq:SNGX ) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte...